NUVB Share Price Performance
US$6.83
4.09 (149.27%)
47.9% undervalued intrinsic discount
US$13.11
Fair Value
Price US$6.83
AnalystConsensusTarget US$13.11
AnalystHighTarget US$19.70
AnalystLowTarget US$7.00
Fair ValueUS$13.11
Share Pricen/a
Nuvation Bio Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 40 Fair Values set on narratives written by author
NUVB Community Narratives
AN
Fair Value
·Fair Value US$13.11 47.9% undervalued intrinsic discount
Emerging Glioma Therapy And Lung Cancer Expansion Will Transform Long Term Oncology Franchise
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value
·Fair Value US$19.7 65.3% undervalued intrinsic discount
ROS1 Lung Cancer Leadership And Glioma Opportunity Will Transform Long Term Oncology Impact
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$7 2.4% undervalued intrinsic discount
RNA Testing And Glioma Program Will Shape Long Term Prospects Despite Near Term Uncertainty
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Emerging Glioma Therapy And Lung Cancer Expansion Will Transform Long Term Oncology Franchise
Nuvation Bio is betting that its lung cancer drug keeps gaining traction as more patients get tested the right way and the treatment expands into earlier-stage disease. The bigger swing is a next program aimed at hard-to-treat brain tumors, which could add a second growth engine—but it may take years to prove out.Read more
AN
US$13.11
47.9% undervalued intrinsic discount
Fair Value
Profit Margin
2.27%
Future PE
576.7x
Price in 2029
US$16.17
RNA Testing And Glioma Program Will Shape Long Term Prospects Despite Near Term Uncertainty
Nuvation Bio’s first marketed cancer drug could grow only if more patients get the right kind of genetic testing, and that shift is still playing out. Meanwhile, its next big brain cancer program may take years to read out, leaving investors weighing a long wait against the chance of a second meaningful product.Read more
AN
US$7
2.4% undervalued intrinsic discount
Fair Value
Profit Margin
21.44%
Future PE
37.51x
Price in 2029
US$8.59
ROS1 Lung Cancer Leadership And Glioma Opportunity Will Transform Long Term Oncology Impact
Nuvation Bio’s lung cancer drug is gaining traction, and wider testing could help more patients get diagnosed and treated over time. The bigger question is whether its next program in brain cancer can deliver on a long, slow timeline while competition and global pricing decisions shape how far growth can go.Read more
AN
US$19.7
65.3% undervalued intrinsic discount
Fair Value
Profit Margin
20.21%
Future PE
67.61x
Price in 2029
US$24.16
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
NUVB: Safusidenib Glioma Data Will Drive Future Upside Potential
Fair Value: US$13.11 47.9% undervalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NUVB: Glioma Data And Lung Cancer Progress Will Shape Future Upside And Risks
Fair Value: US$7 2.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NUVB: Convertible Notes Raise Will Support Advancing Lead Oncology Portfolio
Fair Value: US$19.7 65.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nuvation Bio Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.43
- 88.18%
- -88.19%
- 162.5%
About NUVB
- Founded
- 2018
- Employees
- 305
- CEO
- WebsiteView website
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
